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ABSTRACT: Recently, the World Health Organization approved the
nifurtimox−eﬂornithine combination therapy for the treatment of human
African trypanosomiasis, renewing interest in nitroheterocycle therapies for
this and associated diseases. In this study, we have synthesized a series of
novel 5-nitro-2-furancarboxylamides that show potent trypanocidal activity,
∼1000-fold more potent than nifurtimox against in vitro Trypanosoma brucei
with very low cytotoxicity against human HeLa cells. More importantly, the
most potent analogue showed very limited cross-resistance to nifurtimox-
resistant cells and vice versa. This implies that our novel, relatively easy to
synthesize and therefore cheap, 5-nitro-2-furancarboxylamides are targeting
a diﬀerent, but still essential, biochemical process to those targeted by
nifurtimox or its metabolites in the parasites. The signiﬁcant increase in
potency (smaller dose probably required) has the potential for greatly
reducing unwanted side eﬀects and also reducing the likelihood of drug
resistance. Collectively, these ﬁndings have important implications for the future therapeutic treatment of African sleeping
sickness.
■ INTRODUCTION
Infectious diseases caused by parasitic protozoa aﬀect ca. 15% of
the global population and more than 65% of the population in
the Third and developing world, yet current drug therapies for
protozoan infections are woefully inadequate. As protozoan
infections take their toll predominantly in the developing world,
market forces are insuﬃcient to promote the development of
novel antiprotozoan drugs. In 2000, only ca. 0.1% of global
investment in health research was spent on drug discovery for
tropical diseases.
One such neglected parasitic disease is human African
trypanosomiasis (HAT) or African sleeping sickness, which is
caused by the protozoan parasite Trypanosoma brucei. TheWorld
Health Organization (WHO) estimates that HAT constitutes a
serious health risk to 60 million people in sub-Saharan Africa.
The WHO also estimates that there are <30000 new cases per
year in sub-Saharan Africa and at present an annual death toll of
∼8000.1
The related disease in cattle, cattle trypanosomiasis or Nagana,
also represents a major health concern due to its devastating
economic (estimated by the WHO to cause an annual economic
loss of ∼US$4 billion), social, and nutritional impact on African
families. As such, the total burden of trypanosomiasis translates
into 1598000 disability-adjusted life years (DALY). This is on a
par with big killers such as tuberculosis and malaria.2,3
Treatment of HAT is solely dependent upon a repertoire of
four drugs: suramin (1), pentamidine (2), melarsoprol (3), and
eﬂornithine (4) (Figure 1). These therapies are often toxic,
diﬃcult to administer, and increasingly have an acquired drug
resistance, highlighting the urgent need for new, more eﬀective
drug therapies. Developed before the 1950s, suramin (1) and
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Figure 1. Structures of clinic drugs 1−5 for sleeping sickness and clinic
phase I drug Fexinidazole (6).
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melarsoprol (3) are used for chemotherapy of the early stage of
the disease (Trypanosoma brucei rhodesiense), as is pentamidine
(2) (Trypanosoma brucei gambiense). The arsenical melarsoprol
(3) is extremely toxic, with death in ∼6% of cases and treatment
failure rates of as high as 30% in certain areas. Treatment of the
second stage of the disease, where the parasites cross the blood−
brain barrier and invade the central nervous system, is limited to
melarsoprol (3) and eﬂornithine (4), the ornithine decarbox-
ylase inhibitor (diﬂuoromethylornithine).4,5
Nifurtimox (5) (Figure 1), is often used to treat Chagas’
disease, caused by Trypanosoma cruzi, and has been used as a
monotherapy for melarsoprol-refractory HAT on compassionate
grounds despite its low eﬃcacy and severe toxicity. The recent
introduction of a nifurtimox−eﬂornithine combination therapy
(NECT) by WHO in the Model Lists of Essential Medicines has
been seen as highly advantageous in terms of cost, logistics, and
human resources in areas of poverty. Patients given NECT,
consisting of oral nifurtimox over 10 days with eﬂornithine (4)
infusions for 7 days, were found to fair just as well as those given
the eﬂornithine monotherapy, with cure rates of around 97%.2
The use of NECT has renewed general interest in the use of
nitroheterocyclic compounds to treat a wide range of infectious
disease, including tuberculosis and hepatitis C.6−8 This increased
awareness of the potential of nitroheterocyclic compounds has
led to the reinvestigation of fexinidazole (6) (Figure 1), which is
presently in clinical trials against both early- and late-stage
African sleeping sickness.6−8
Alarmingly, it has been shown that T. brucei nifurtimox-
resistant cells show cross-resistance to other nitro-containing
drugs, including fexinidazole, that are currently in clinical
trials.9,10 Several diﬀerent types of studies on nitroheterocycles
have shed some light on this observed drug resistance. Genome-
wide RNAi screens of nifurtimox and benznidazole (another
trypanocidal nitroheterocyclic drug) resistant T. brucei have
identiﬁed that a decrease in nitroreductase activity is linked to
nifurtimox resistance.9,10 This was conﬁrmed by showing that
genetic deletion of one allele of the T. brucei’s nitroreductase led
to nifurtimox resistance. Likewise, the overexpression of this
nitroreductase, but not the alternative proposed prostaglandin
F2α synthase and cytochrome P450 reductase, in T. brucei
resulted in increased susceptibility to nifurtimox.11 Collectively,
it is clear that this type I T. brucei nitroreductase, a NAD(P)H
dependent, ﬂavin binding protein, is involved in the reductive
activation of nifurtimox. The nitroreductases mediate a series of
two-electron reductions of the nitro group to a nitroso
intermediate, then to a hydroxylamine, and eventually to the
corresponding amine. However, the true function of the T. brucei
mitochondrial nitroreductase is unknown, but its essentiality may
explain why only a single allele deletion/mutation is associated
with nifurtimox resistance.10,11
As well as the development of nifurtimox-resistance and its
cross-resistance to other nitro-containing drugs, side eﬀects are
also amajor problem for nitro-containing drugs. For example, the
adverse oﬀ-target side eﬀects with nifurtimox lead to treatment
cessation in over 30% of patients with Chagas’ disease.12 The
most common side eﬀects are anorexia, loss of weight, psychic
alterations, excitability or sleepiness, and digestive manifestations
such as nausea or vomiting and occasionally intestinal colic and
diarrhea.13 Various human enzymes have been identiﬁed to be
capable of 5-nitrofuran reduction in vitro, in cells, or tissues.14−16
Recently, we have elucidated in collaboration with the Patton
Laboratory a possible role of aldehyde dehydrogenase 2
(ALDH2) in the toxicity caused by 5-nitrofuran containing
drugs such as nifurtimox.17
While considerable eﬀort has gone into the synthesis of
nitroaromatic containing compounds over the years,18−23 there
remains several unexplored areas of chemical space. For example,
in the context of nifurtimox, most of the eﬀorts have been
focused on changing either the furan ring to other heterocycles
(such as imidazole) or changing the substituent in the hydrazone
motif,18−23 with limited increases in activity compared to
nifurtimox. Recently, two new types of typanocidal compounds,
nitrobenzylphosphoramide mustards (for example see com-
pound 7, Figure 2)24 and aziridinyl nitrobenzamides, have been
developed to target speciﬁcallyT. brucei type I nitroreductase, the
best having an EC50 ∼ 1 μM against both T. brucei and T.
cruzi.25,26 Several 5-nitro-2-furancarboxylamide containing com-
pounds have been reported to have potent antituberculosis and
antimicrobial activity,27−30 however, very few 5-nitro-2-furan-
carboxylamides are reported to have typanocidal activity,
primarily low activity against T. cruzi.31,32 A nifurtimox analogue
(8) (Figure 2) showed trace activity against T. cruzi in a mouse
model.33 The best 5-nitro-2-furancarboxylamides identiﬁed thus
far, 9 and 10, have EC50 values of 42 and 262 nM, respectively,
against T. cruzi amastigotes (Figure 2) but have not been tested
againstT. brucei to the best of our knowledge.34 Several 5-nitro-2-
furancarbohydrazides possess activity against T. brucei with the
best, compound 11, having an EC50 of 0.13 μM but low
selectivity against human cells.35
In this study, we report that our recently discovered nitrofuran
NFN1 (12a)17 also shows promising activity against T. brucei in
vitro. We have therefore synthesized a series of 5-nitro-2-
furancarboxylamide analogues of 12a. A lack of cross-resistance
with nifurtimox and signiﬁcantly increased (2−3 orders of
magnitude) trypanocidal activity has important implications for
the future therapeutic use of these nitrofuran containing
Figure 2. Structures of some reported bioactive nitroaromatic compounds 7−12a.
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compounds in the treatment of HAT, instead of, or in
combination with, nifurtimox.
■ RESULTS AND DISCUSSION
Chemistry. 5-Nitrofurans 12a−k were prepared by acylation
of the corresponding 2-amino-thiophenes 13a−k with 5-nitro-
furancarboxylic acid chloride 14a (Scheme 1, Table 1 for
substituents). The required 2-amino-thiophenes 13a−h were
prepared using the Gewald multicomponent reaction with
various combinations of the 2-cyanoacetyl esters or amides
(15a−g) with aldehydes (16a or 16b) and elemental sulfur (see
Supporting Information Table S1 for details).36,37 13h was O-
silyl-protected before coupling to 14a. This reaction gave 12h
directly as a result of in situ removal of the silyl-protecting group.
Thiophene 13i was prepared by hydrolysis of 13a and 13j
prepared by catalytic amination of 2-iodothiophene using CuI
and L-proline.38 13k and 13l (Table 2) were commercially
available. Reaction of 13a (R2 = Et, R3 = CO2Et) with 14b gave
control compound 18a. An analogous reaction of 14b with
aniline gave 18b (Table 2). Furan ester 19 was commercially
available.
Analogues 20a−c and 21 (Table 2) based on 12g but
containing alternative nitroaromatic rings were prepared by
coupling the corresponding acid chlorides with 13g (see ESI for
details). Similarly, reaction of 14a with a range of amines and
anilines led to the synthesis of 22a−q (Scheme 1).
Demethylation of 22o to give 22r was followed by selective O-
allylation to give 22s (Scheme 2), the structure of which was
conﬁrmed by X-ray crystallographic analysis (data not shown).
When a longer reaction time and an excess amount of allyl
bromide was used in the O-allylation of 22r, the diallylated
analogue 22t was formed (Scheme 2). Mono-O-allylation of 22p
gave 22u (Scheme 2). Methylation of 22q to give 22v was
achieved using MeI under basic conditions in moderate yield
(Scheme 2). Conversion of 5-nitrofuran aldehyde 23 to imines
24a or 24b enabled the synthesis of the corresponding amines
25a and 25b using standard reductive amination conditions
(Scheme 2).
Structure−Activity Relationships. In comparison to
nifurtimox, NFN1 was 2 orders of magnitude more potent
with an EC50 of 31.3 ± 3.1 nM (Table 1, cf. entries 1 and 2). The
nitro group in NFN1 was found to be essential with no activity
being observed up to the solubility limit of 18a (entry 3).
Removal, or worse, elongation of the alkyl substituent in NFN1
led to reduced activity (cf. entry 2 and entries 4 and 5,
respectively), and while removal of the ester group initially
appeared to be tolerated in the R2 = H series (cf. entries 4 and 6),
it was found that the methyl and n-butyl ester analogues (12c and
2d) of NFN1 had similar activity to NFN1 (cf. entry 2 and entries
7 and 8, respectively). Conversion of the ester groups in NFN1
and 12d to the corresponding amides in 12e and 12f led to a
signiﬁcant loss in activity (cf. entries 2 and 8 with entries 9 and
10, respectively). This observation, coupled with the decrease in
activity associated with amide 12h (entry 11), may be explained
by the fact that hydrolysis of the ester groups in 12a−d and 12k
in the parasite gives the corresponding carboxylic acid-containing
bioactive metabolites, something that is unlikely to occur for the
amides 12e and 12f. However, acid 12i showedmuch less activity
with an EC50 of 959.0± 33.9 nM (entry 12), whichmay be due to
a lack of cell permeability. The primary amide 12g was found to
be the most active thiophene-containing analogue with an EC50
of 17.3 ± 2.4 nM (entry 13). Furthermore, analogues 12a−k
showed no signiﬁcant toxicity against the human HeLa cell line
even at a concentration above 20 μM. The highly selective
toxicity of these analogues against the parasite suggests these
nitrofuran analogues have real potential for therapeutic
applications.
Encouraged by the potent activity of 12g (Table 1), it was
decided to prepare more analogues based on this structure.
Fragments 19 and 13g along with 13l were shown to be inactive
against T. brucei, suggesting that both the 5-nitrofuran and
thiophene fragments are required (Table 2, cf. entry 1 and entries
2−4, respectively). Changing the nitrofuran motif in 12g to
either a nitrophenyl or nitropyrazole ring also led to a 100-fold or
more drop in activity (cf. entry 1 and entries 5−8, respectively).
Interestingly, the position of the nitro group in the nitrophenyl
ring had an inﬂuence as 20b, an analogue with the nitro group in
the meta-position, was more active than either 20a (ortho-NO2)
or 20c (para-NO2). Studies next focused on replacing the
thiophene motif in 12a−k. By incorporating a cyclohexyl ring to
give 22a, a 10-fold decrease in activity was observed compared to
12g (entry 9), while the phenyl (22b) and benzyl (22c)
analogues were essentially equipotent with 12g (cf. entry 1 and
entries 10 and 11, respectively). Incorporation of a nitrogen atom
into the 2-position of the phenyl ring in 22c to give 22d led to a
10-fold drop in activity (entry 12). The nitrofuran group in 22b
was shown to be essential (cf. entries 10 and 13), and the amide
linkage in 22b and 12g was also shown to be important, as the
Scheme 1. Synthetic Route to 5-Nitro-2-furancarboxylamide
Analogues 12a−ka
aReagents and conditions: (a) (i) (COCl)2, DCM/DMF, RT, 2 h, (ii)
R1NH2, Et3N, DCM, 52% for 15d, 49% (15e), 37% (15g); (b) S8, 16a
or 16b, Et2NH, DMF, RT, o/n, 66% for 13a, 59% (13b), 76% (13c),
53% (13d), 49% (13e), 46% (13f), 48% (13g), 46% (13h), for
synthesis of 13i−j see ESI, 13k and 13l were commercially available;
(c) 13a−k, Et3N, DCM, RT with 14a, 68% for 12a, 62% (12b), 65%
(12c), 58% (12d), 57% (12e), 57% (12f), 54% (12g), 47% (12h),
25% (12i), 41% (12j), 51% (12k), with 14b, 56% for 18a; (d) RNH2,
Et3N, DCM, RT with 14a, 65% for 22a, 61% (22b), 72% (22c), 67%
(22d), 37% (22e), 50% (22f), 45% (22g), 41% (22h), 66% (22i), 39%
(22j), 51% (22k), 73% (22l), 51% (22m), 68% (22n), 67% (22o),
69% (22p), 48% (22q), with 14b 73% for 18b (see Table 2 for
structure of 18b). (a) 15a−c and 15f were commercially available; (b)
15d, 15e, and 15g were prepared from 17; (c) for R2 and R3
substituents, see Table 1; (c) for R6 substituents, see Tables 2 and 3.
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amine analogues 25a and 25b showed a dramatic decrease in
activity (entries 14 and 15, respectively).
On the basis of the potent activity of 22b, the eﬀect of
incorporating additional substituents into the phenyl ring was
investigated (Table 3). Substitution at the para-(R3) and meta-
(R2 or R4)-positions with either electron-withdrawing (entries 3
and 5−7, respectively) or electron-donating groups (entries 4
and 8, respectively) proved detrimental, with the exception of the
incorporation of the meta-CF3 group in 22e (EC50 of 22e = 4.69
± 0.14 nM, entry 2). Interestingly, incorporation of a meta-CF3
into the phenyl ring of the benzyl analogue 22c (Table 2) gave
analogue 22l, which had an EC50 = 17.4 ± 3.0 nM, suggesting
that the use of a phenyl substituent (as in 22e) may be preferred
to the benzyl substituent in 22l. Combining the meta-CF3
substituent with either an additional meta-methoxy- or a second
meta-CF3 substituent led to a decrease in activity (entries 9 and
11, respectively), whereas the meta-CF3 group was able to
override the eﬀect of a para-methoxy substituent (cf. entries 8
and 12). Incorporation of a para-hydroxy in both the meta-CF3
and unsubstituted series led to a signiﬁcant reduction in activity
(entries 13 and 14, respectively), but extending the para-alkoxy
chain from methoxy in 22o to allyloxy led to the most active
compound prepared, analogue 22s, which had an EC50 against T.
brucei of 2.4 ± 0.3 nM (entry 15). The positive role of the para-
allyloxy substituent was also observed in the unsubstituted series
(cf. entries 8 and 16). The incorporation of an additional allyloxy
substituent on the amide nitrogen in 22s led to a signiﬁcant loss
in activity for 22t (cf. entries 15 and 17).
Interestingly, the lack of signiﬁcant biological activity displayed
by the 2-triﬂuoromethylphenol 22r, e.g., EC50 value of 2.2 ± 0.1
μM versus 2.4 ± 0.3 nM for 22s or 7.8 ± 0.3 nM for 22o, might
be due to the high instability of 22r in the tested conditions as the
result of ﬂuorine elimination generating a quinone methide, as
previously reported.39,40 Masking the phenol as allyl or methyl
ethers, e.g., as in 22s or 22o, respectively, restored the
trypanocidal activity against T. brucei.
Finally, the special role played by themeta-CF3 substituent was
further highlighted by a more than 5-fold drop in activity
observed on its replacement by a meta-CH3 substituent (cf.
entries 12 and 18). As was the case for analogues 12a−k, all the
analogues shown in Tables 2 and 3 showed low toxicity against
the human HeLa cell line.
■ CROSS-RESISTANCE STUDIES
The striking increase in potency of the 5-nitro-2-furancarbox-
ylamide analogues compared to nifurtimox against bloodstream
T. brucei suggests they have a diﬀerent or possibly additional
mode of action to that of nifurtimox, i.e., in addition to the
activation by the T. brucei nitroreductase. To investigate this
possibility, it was decided to generate drug resistant cell lines to
nifurtimox and the most potent of the 5-nitro-2-furancarbox-
ylamide analogues, 22s (EC50 = 2.4± 0.3 nM). This would allow
subsequent cross-resistance studies to be conducted. Previous
lab-generated nifurtimox-resistant strains have shown that
deletion or mutation of one of the alleles of the nitroreductase
confers resistance.9,10
Table 1. SAR Study of Analogues 12a−12k
aFor structure, see Figure 1. bSee ref 17. cNot applicable as essentially no activity against T. brucei was observed for 12i.
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As with these previous studies, nifurtimox-resistant parasites
were generated easily by culturing bloodstream T. brucei in the
continuous presence of nifurtimox. A stepwise increase in the
concentrations of nifurtimox, initially starting at 1.5 μM,
increasing to 2.5, 4, 5, 7.5, 10, 15, 20, 25, 30, 40, 45, and 50
μM on days 2, 5, 9, 14, 23, 39, 55, 65, 76, 90, 109, and 120,
respectively, was used (Figure 3A). At 143 days, these
nifurtimox-resistant parasites were cloned by serial dilution
while maintaining the 50 μM nifurtimox.
Compound 22s-resistant parasites were initially harder to
generate. Selection studies started at 1 nM of 22s, increasing to 2,
3, 5, 7.5, 10, 15, 20, 25, 30, 35 40, and 50 μM on days 2, 5, 9, 26,
36, 47, 58, 70, 76, 103, 130, and 148, respectively (Figure 3B). At
160 days, the 22s-resistant parasites were cloned by serial
dilution while maintaining a 50 nM concentration of 22s. Both of
the drug-resistant cell lines were stable for 30 days in the absence
of their respective drugs. The nifurtimox-resistant parasites had a
doubling time of∼11.5± 0.6 h compared to wild-type∼7.8± 0.4
h, while 22s-resistant parasites had a doubling time of ∼13.3 ±
1.1 h.
The sensitivities of the cloned nifurtimox-resistant and 22s-
resistant parasites to nifurtimox, 22s, and the diamidine
pentamidine (2) were determined and compared to wild-type
cells. The nifurtimox-resistant cells did not greatly alter (∼2-fold
increase) the sensitivity to pentamidine (2) compared to wild-
type cells (Table 4), in accordance with previous lab generated
nifurtimox-resistant cell lines.9,10 22s-resistant parasites also
showed very little alteration in the EC50 (1.1 ± 0.1 nM) of
pentamidine (2) compared to that of wild-type cells (Table 4).
The nifurtimox-resistant cells were found to be 9−10-fold less
sensitive to nifurtimox than wild-type cells, with EC50s of 20.9 ±
1.7 and 2.1 ± 0.2 μM, respectively (Table 4), in accordance with
previous ﬁndings.9 22s-resistant cells were found to be ∼14-fold
less sensitive to 22s than wild-type cells, with EC50s of 29.3± 2.0
and 2.4 ± 0.3 nM, respectively (Table 4). Even at this level of
resistance, 22s is still ∼70 times more potent than nifurtimox in
wild-type T. brucei.
To investigate cross-resistance between nifurtimox and 22s,
the EC50s of the drug-resistant cell lines versus the alternative
nitrofuran containing compounds were determined (Table 4).
The results showed that nifurtimox and 22s showed a low level of
cross-resistance. Nifurtimox-resistant cells showed a ∼3-fold
increase in the EC50 of 22s, while nifurtimox also showed∼3-fold
increase in the EC50 against 22s-resistant cells. These ﬁndings
Table 2. SAR Study of Series 2 Analogues
aNot applicable as no activity or low activity against T. brucei was observed for 18b and 25a.
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imply that these two nitrofuran compounds, nifurtimox and 22s,
are trypanocidal as a result of primarily targeting diﬀerent
biochemical process within the parasites. However, the low level
of cross-resistance suggests there may be some minor overlap in
the mode of action. This issue is discussed in more detail later.
These ﬁndings have important implications for the therapeutic
use of this new generation of nitrofuran compounds as part of
novel combination therapies or more importantly potentially
replacing nifurtimox in a clinical setting.
As nifurtimox and 22s apparently act through primarily
diﬀerent modes of action, this suggests that their combined
action against the parasite may be synergistic. As such, a series of
EC50s were determined for 22s in the presence of various
concentrations of nifurtimox (Figure 4). At low concentrations
of nifurtimox (<700 nM), synergy can be observed as the EC50s
are below the straight diagonal line that represents what would be
expected for an additive trypanocidal eﬀect of the two
compounds. Above concentrations of 700 nM nifurtimox,
there is a distinct lack of synergy; if anything, competition
occurs between the two inhibitors. This, taken together with the
observed low level of cross-resistance (Table 4), may indicate
that nifurtimox at high concentrations is competing with the
same biochemical activation process which is normally targeted
by 22s. This further highlights the possible multitarget nature for
nifurtimox that has been suggested previously.9−14 This type of
information is relevant for the potential pharmacological
applications of these novel nitro-furancarboxylamides as a
combinational therapy would likely lead to the use of lower
nifurtimox doses.
It was decided to test some of the 5-nitro-2-furancarbox-
ylamides from this study against cultured T. b. rhodesiense, one of
the human-infective subspecies (Table 5). The potency of a
selection of analogues against T. b. rhodesiense were similar to
those observed for T. b. brucei, suggesting that these novel
nitrofurans could be considered lead candidates for the next step
toward a novel treatment for HAT, as well as the related animal
disease, Nagana.
■ CONCLUSIONS
In this work, we designed and synthesized a series of nitrofuran-
containing analogues that were tested for trypanocidal and
cytotoxicity activity against cultured bloodstream form T. b.
brucei and human HeLa cells, respectively. The analogue 22s
showed an EC50 of 2.4 ± 0.3 nM, 3 orders of magnitude more
potent than nifurtimox with a selectivity index >8000. SAR
studies showed that all fragments of the compounds were
required for activity. In addition, both the nitrofuran and amide
functional groups and the amide NH were necessary. The
thiophene ring in the starting analogue 12a can be replaced by a
range of other substituents. However, in the thiophene series, an
ester group was required and is likely converted to the
corresponding carboxylic acid in the parasite. Several of our
analogues were also tested against T. b. rhodesiense, showing
analogous activity to that in T. b. brucei. This exciting result
demonstrates that this series of analogues is worthy of further
study as a potential therapy for HAT.
Importantly, the cross-resistance studies showed that the 5-
nitro-2-furancarboxylamide analogues in this study have low
levels of resistance to nifurtimox-resistant cells and vice versa
while showing no resistance to pentamidine (2). These results
indicate that the trypanocidal mode-of-action of the 5-nitro-2-
furancarboxylamide analogues in this study does not rely upon
nitroreductase activation unlike nifurtimox and other nitro-
heterocyclic compounds that are presently in clinical trials
against HAT. However, the lack of expected synergy at high
concentrations of nifurtimox suggests it may be interacting with
the novel mode of action which is primarily targeted by our novel
5-nitro-2-furancarboxylamide analogues.
Our data suggest that these new 5-nitro-2-furancarboxylamide
analogues have a potential therapeutic implication as a single
reagent in regard to potency and selectivity. Also, combination
therapies can be considered due to their low cross-resistance to
other trypanocidal drugs. This idea is supported by our results
that show there is a synergistic relationship between nifurtimox
and 22s at concentrations of nifurtimox of <700 nM (Figure 4).
While there remain many more challenges to the development of
a HAT therapeutic that have not been addressed here (see
Supporting Information Table S6 for a detailed discussion of
drug-likeness parameters associated with our analogues), we
believe that the novel mechanistic and high in vitro potency of
the antitrypanosomal compounds presented here renders them
worthy of further study in the drug discovery context.
■ EXPERIMENTAL SECTION
Biology. Materials. All materials unless stated were purchased from
either Sigma-Aldrich or Invitrogen.
Trypanocidal Studies. The trypanocidal activity over a 72 h period
was determined using the Alamar Blue viability, as described
previously.41 Nifurtimox, pentamidine, melarsoprol, and various novel
nitrofuran analogues were tested against Trypanosoma brucei brucei
bloodstream-form (strain 427) or drug-resistant strains were cultured at
37 °C inHMI9medium supplemented with 10% fetal calf serum and 2.5
μg mL−1 G418 as described previously.42 T. brucei rhodesiense (strain
Z310) were cultured in a similar manner but in the absence of G418. For
the synergistic experiments, various concentrations of nifurtimox (0,
200, 400, 600, 800, 1000, 1500, 2000, and 2400 nM) were used in
conjunction with a serial dilution of 22s. Experiments were conducted in
replicates of four; the data was ﬁtted using GraFit software to obtain
EC50 ± standard deviations and slope factors.
Cytotoxicity Studies. Cytotoxic aﬀects against HeLa cells were
determined in a similar manner. Brieﬂy, the cells were cultured in
DMEM supplemented with 10% fetal calf serum and 2 mM L-glutamine.
Scheme 2. Synthetic Routes to Series 2 and Series 3
Nitrofurancarboxylamidesa
aReagents and conditions: (a) pyridine hydrochloride, 160 °C, MW, 5
min, 52%; (b) 22r or 22p, allyl bromide (2 or 10 equiv), K2CO3,
acetone, RT, 2 h for 22s (75%), 24 h for 22t (55%), 24 h for 22u
(72%), 22q, MeI, K2CO3, acetone, 3 h, for 22v (51%); (c) aniline or
13g, DCM, RT, 89% for 24a, 63% for 24b; (d) NaBH4, DCM, RT,
79% for 25a, 87% for 25b.
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Cells were plated at initial cell concentration of 2 × 104 cells/well and
incubated with the compounds for ∼65 h prior to addition of Alamar
Blue solution for a further 5 h.
Generation of Drug-Resistant T. brucei Cell Lines.Drug-resistant T.
brucei cell lines were generated by subculturing bloodstream
trypanosomes in the continuous presence of either nifurtimox or
compound 22s. Parasites were exposed to stepwise-increased
concentrations of drug, starting at appropriate sublethal concentrations,
until they were routinely growing between 20 and 25 times their
respective original EC50s. After 150−160 days in culture, drug-resistant
parasites were cloned by limiting dilution and used for further study. Cell
doubling times were determined in replicates of 4 over a 96 h period.
Chemistry. General. Chemicals and reagents were obtained from
either Aldrich or Alfa-Aesar, except nifurtimox (5) from Bayer
Argentina. All reactions involving moisture sensitive reagents were
performed in oven-dried glassware under a positive pressure of argon.
Dichloromethane (DCM) was obtained dry from a solvent puriﬁcation
system (MBraun, SPS-800). Melting points were recorded in open
capillaries using an Electrothermal 9100 melting point apparatus.
Infrared spectra were recorded on a Perkin-Elmer Spectrum GX FT-IR
spectrometer using thin ﬁlms on KBr (for solids) discs or Nujol (for
liquids). Low resolution (LR) and high resolution (HR) electrospray
mass spectral (ES-MS) analyses were acquired by electrospray
ionization (ESI) within the School of Chemistry, University of St.
Andrews. Low and high resolution ESI MS were carried out on a
Micromass LCT spectrometer or at a high performance orthogonal
acceleration reﬂecting TOF mass spectrometer coupled to a Waters
2975 HPLC. Nuclear magnetic resonance (NMR) spectra were
acquired either on a Bruker Avance 300 (1H, 300.1 MHz; 13C, 75.5
MHz) or on a Bruker Avance 400 (1H, 400 MHz; 13C, 100.1 MHz)
spectrometer and in the deuterated solvent stated. 13C NMR spectra
were acquired using the PENDANT or DEPTQ pulse sequences.
For characterization of 2-aminothiophenes 13a−k, compounds 20a−
c, 21, intermediates, and other known compounds, please see
Supporting Information. The prepared analogues were analyzed by
HPLC with purity above 95% (Supporting Information).
General Procedure for the Synthesis of Furancarboxyl Amides
12a−k, 18a−b, and 22a−q. The furoic acid chlorides 14a and 14b
were prepared in situ: thionyl chloride (1.10 equiv) was added dropwise
to a mixture of 5-nitrofuran-2-carboxylic acid or 2-furoic acid (1.10
equiv) and triethylamine (1.50 equiv) in DCM (0.4 M) under a N2
atmosphere. The reaction mixture was stirred at room temperature for 5
Table 3. SAR Study of Series 3 Analogues
aStructure of 5-nitro-N-(3-(triﬂuoromethyl)benzyl)furan-2-carboxamide (22l).
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h. Then crude 14a or 14b was added to another ﬂask containing the
corresponding amine or aniline (1.00 equiv) and triethylamine (2.00
equiv) in DCM (0.4 M). The reaction mixture was stirred at room
temperature for 5 h. The solvent was then removed under reduced
pressure, and the crude reaction mixture was puriﬁed by column
chromatography.
Details of the synthesis of furancarboxyl amides 12a, 12g, 22e, 22h,
and 22s are given here in the main text of the paper; the remainder
(12b−f, 12h−k, 22a−d, 22f, 22g, 22i−t, and 22u) are described in the
Supporting Information.
Ethyl 5-Ethyl-2-(5-nitrofuran-2-carboxamido)thiophene-3-car-
boxylate (12a). The general procedure was followed using 2-
amiothiophene 13a (3.99 g, 20.0 mmol). The crude reaction mixture
was puriﬁed by column chromatography on silica gel (5:1, hexane/ethyl
Figure 3. Generation of nifurtimox and 22s resistance cell-lines:
schematic representation of the generation of a (A) nifurtimox-resistant
and (B) 22s-resistant cell lines in T. brucei. Each point represents the
concentration at that time point when cells were checked and divided if
required.
Table 4. Cross-Resistance Studies, EC50s of Wild-Type and Cloned Drug-Resistant Cell Lines
aEC50 literature value of nifurtimox in wild-type T. brucei 2.4 ± 0.1 μM and in nifurtimox resistant cells 20.1 ± 0.9 μM.
9 bEC50 literature value of
pentamidine (2) in wild-type T. brucei 0.95 ± 0.02 nM and in nifurtimox resistant cells 2.6 ± 0.1 nM.9
Figure 4. Studies of possible synergy between nifurtimox (5) and 22s in
T. brucei.
Table 5. EC50s of Typical Series 1 and Series 2 Analogues
against T. b. rhodesiense
aEC50 literature value of nifurtimox in T. b. rhodesiense 1.5 μM.
43
bEC50 literature value of melarsoprol against T. b. rhodesiense 6 nM .
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acetate) to aﬀord the product as an orange solid (4.60 g, 13.6 mmol,
68%); mp 127−128 °C. IR (KBr) νmax = 3120 (s) (NH), 2958 (m) (C−
H), 1667 (s) (CO), 1569 (s), 1531 (s) (NO2), 1350 (s) (NO2), 1280
(s) (C−O), 1266 (s) (C−O) cm−1. 1H NMR (400MHz, acetone-d6): δ
11.75 (br s, 1H), 7.58 (d, 3J = 3.9 Hz, 1H), 7.42 (d, 3J = 3.9 Hz, 1H), 6.85
(t, 4J = 1.1 Hz, 1H), 4.28 (q, 3J = 7.1 Hz, 2H), 2.67 (dq, 3J = 7.5 Hz, 4J =
1.1Hz, 2H), 1.27 (t, 3J = 7.1Hz, 3H), 1.17 (t, 3J = 7.5 Hz, 3H). 13CNMR
(100 MHz, acetone-d6): δ 165.8 (C), 153.6 (C), 153.1 (C), 147.4 (C),
145.6 (C), 139.2 (C), 120.6 (CH), 118.6 (CH), 115.0 (C), 113.8 (CH),
61.7 (CH2), 23.2 (CH2), 15.9 (CH3), 14.6 (CH3). LRMS (ES
+): m/z
(%) 360.87 (100) [M + Na]+. HRMS (ES+): m/z calcd for
C14H14N2O6NaS [M + Na]
+, 361.0470; found, 361.0469.
N-(3-Carbamoyl-5-ethylthiophen-2-yl)-5-nitrofuran-2-carboxa-
mide (12g). The general procedure was followed using 2-
amiothiophene 13g (170 mg, 1.00 mmol). The crude reaction mixture
was puriﬁed by column chromatography on silica gel (1:1, hexane/ethyl
acetate) to aﬀord the product as a yellow solid (167 mg, 0.54 mmol,
54%); mp (dec.) > 224 °C. IR (KBr) νmax = 3476 (m), 3341 (m) (NH),
3211 (m), 3143 (m), 1659 (s) (CO), 1591 (s), 1565 (s), 1534 (s)
(NO2), 1349 (s) (NO2), 739 (m) cm
−1. 1H NMR (400 MHz, acetone-
d6): δ 7.56 (d,
3J = 3.9 Hz, 1H), 7.36 (d, 3J = 3.9 Hz, 1H), 7.05 (t, 4J = 1.1
Hz, 1H), 6.80 (br s, 1H), 2.66 (dq, 3J = 7.5 Hz, 4J = 1.1 Hz, 2H), 1.16 (t,
3J = 7.5 Hz, 3H). 13C NMR (100 MHz, acetone-d6): δ 168.3 (C), 153.4
(C), 152.9 (C), 148.0 (C), 144.2 (C), 138.9 (C), 119.4 (CH), 117.9
(CH), 117.0 (C), 113.7 (CH), 23.4 (CH2), 15.8 (CH3). LRMS (ES
+):
m/z (%) 331.91 (100) [M + Na]+. HRMS (ES+): m/z calcd for
C12H11N3O5NaS [M + Na]
+, 332.0317; found, 332.0323.
5-Nitro-N-(3-(triﬂuoromethyl)phenyl)furan-2-carboxamide (22e).
The general procedure was followed using 3-(triﬂuoromethyl)aniline
(622 μL, 5.00 mmol). The crude reaction mixture was puriﬁed by
column chromatography on silica gel (2:1, hexane/ethyl acetate) to
aﬀord the product as a yellow solid (550 mg, 1.83 mmol, 37%); mp
188−189 °C. IR (KBr) νmax = 3271 (m) (NH), 1668 (s) (CO), 1496
(s) (NO2), 1334 (s) (NO2), 1266 (s), 1157 (s) (CF3), 1119 (s) (CF3)
cm−1. 1HNMR (300MHz, acetone-d6): δ 10.37 (br s, 1H), 8.30 (s, 1H),
8.07 (d, 3J = 8.3 Hz, 1H), 7.66 (d, 3J = 3.8 Hz, 1H), 7.61 (d, 3J = 7.9 Hz,
1H), 7.53−7.50 (m, 2H). 13C NMR (75MHz, acetone-d6): δ 156.2 (C),
152.3 (C), 149.2 (C), 140.2 (C), 132.0 (C), 131.2 (CH), 127.3 (C),
125.2 (CH), 122.3 (CH), 118.3 (CH), 118.2 (CH), 114.1 (CH). LRMS
(ES+): m/z (%) 301.05 (100) [M + H]+. HRMS (ES+): m/z calcd for
C12H8N2O4F3 [M + H]
+, 301.0436; found, 301.0428. Anal. Calcd for
C12H7F3N2O4: C, 48.01; H, 2.35; N, 9.33. Found: C, 47.57; H, 2.27; N,
9.05.
5-Nitro-N-(4-(triﬂuoromethyl)phenyl)furan-2-carboxamide (22h).
The general procedure was followed using 4-(triﬂuoromethyl)aniline
(622 μL, 5.00 mmol). The crude reaction mixture was puriﬁed by
column chromatography on silica gel (3:1, hexane/ethyl acetate) to
aﬀord the product a yellow solid (615 mg, 2.01 mmol, 41%); mp 235−
236 °C. IR (KBr) νmax = 3406 (m) (NH), 1697 (s) (CO), 1538 (s),
1528 (s) (NO2), 1323 (s) (NO2), 1129 (s) (CF3), 1115 (s) (CF3), 1069
(s), 855 (s) cm−1. 1H NMR (300 MHz, acetone-d6): δ 10.29 (br s, 1H),
7.94 (d, 3J = 8.6 Hz, 2H), 7.61 (d, 3J = 8.6 Hz, 2H), 7.54 (d, 3J = 3.8 Hz,
1H), 7.40 (d, 3J = 3.8 Hz, 1H). 13C NMR (100 MHz, acetone-d6): δ
155.8 (C), 152.8 (C), 148.8 (C), 142.5 (C), 127.0 (2CH), 126.9 (C),
124.0 (C), 121.3 (2CH), 117.9 (CH), 113.7 (CH). LRMS (ES+): m/z
(%) 301.04 (100) [M +H]+. HRMS (ES+):m/z calcd for C12H8N2O4F3
[M + H]+, 301.0436; found, 301.0432.
N-(4-(Allyloxy)-3-(triﬂuoromethyl)phenyl)-5-nitrofuran-2- carbox-
amide (22s). A mixture of 22r (64 mg, 0.20 mmol, 1.00 equiv), K2CO3
(55mg, 0.40 mmol, 2.00 equiv), and allyl bromide (0.03 mL, 0.40mmol,
2.00 equiv) in acetone (5 mL) was stirred at room temperature for 3 h.
The reaction mixture was then diluted in ethyl acetate (20 mL), washed
with water (10 mL), dried (Na2SO4), and concentrated under vacuum.
The crude reaction mixture was puriﬁed by column chromatography
(3:1, hexane/ethyl acetate) to aﬀord the product as a yellow solid (53
mg, 0.15 mmol, 75%); mp 155−156 °C. IR (KBr) νmax = 3350 (s), 3115
(m) (NH), 1681 (s) (CO), 1611 (m), 1504 (s) (NO2), 1331 (s)
(NO2), 1250 (s) (C−O), 1135 (s) (CF3), 1113 (s) (CF3) cm−1. 1H
NMR (400 MHz, acetone-d6): δ 10.07 (br s), 8.03 (d,
4J = 2.5 Hz, 1H),
7.89 (dd, 3J = 9.1 Hz, 4J = 2.5 Hz, 1H), 7.52 (d, 3J = 3.9 Hz, 1H), 7.35 (d,
3J = 3.9 Hz, 1H,), 7.13 (d, 3J = 9.1 Hz, 1H), 6.02−5.87 (m, 1H), 5.35 (d,
3J = 17.5 Hz, 1H), 5.15 (d, 3J = 10.7 Hz, 1H), 4.64−4.59 (m, 2H). 13C
NMR (100 MHz, acetone-d6): δ 155.5 (C), 153.9 (C), 152.6 (C), 149.1
(C), 133.8 (CH), 131.8 (C), 126.7 (CH), 125.9 (C), 123.2 (C), 120.3
(CH), 117.5 (CH), 117.4 (CH2), 115.1 (CH), 113.7 (CH), 70.08
(CH2). LRMS (ES
+): m/z (%) 378.91 (100) [M + Na]+. HRMS (ES+):
m/z calcd for C15H11N2O5NaF3 [M +Na]
+, 379.0518; found, 379.0526.
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